This week’s Vaccines update highlights recent progress across vaccines and immuno-oncology, spanning early- and late-stage clinical data, novel delivery approaches, and strategic pipeline positioning. Developments range from infectious disease prevention to personalized cancer vaccines, with implications for future trial design and market readiness.
In Today’s Newsletter
Dive deeper
PanChol oral cholera vaccine shows Phase 1 promise [1] [US • 09 Jan 2026]
https://www.cidrap.umn.edu/cholera/novel-cholera-vaccine-shows-promise-phase-1-trial
Key point: PanChol, a live-attenuated oral cholera vaccine, was safe and immunogenic in a Phase 1 adult trial.
Context: Randomized trial in 57 adults; vaccine derived from Vibrio cholerae O1; single-dose design; antibodies capable of killing V. cholerae.
Implication: May influence prescriber choice and payer reviews pending full data.
Clover starts Phase 2 for multivalent respiratory vaccines [2] [Australia • 12 Jan 2026]
https://www.cloverbiopharma.com/media/189.html
Key point: Clover initiated Phase 2 testing of SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) in older adults.
Context: Up to 420 participants aged 60–85; randomized, observer-blinded; protein vaccines using Trimer-Tag prefusion F antigens.
Implication: Signals pipeline investment and modality expansion.
TG4050 neoantigen vaccine shows 100% DFS at two years [3] [12 Jan 2026]
https://www.targetedonc.com/view/phase-i-trial-of-neoantigen-vaccine-shows-100-dfs-rate-in-hnscc
Key point: TG4050 achieved 100% disease-free survival at two years when given post-surgery in HPV-negative HNSCC.
Context: 80-patient randomized study; individualized MVA-based vaccine encoding up to 30 neoantigens; 73% developed T-cell responses.
Implication: May influence prescriber choice and payer reviews pending full data.
IO102–IO103 vaccine plus pembrolizumab in melanoma [4] [13 Jan 2026]
Key point: Phase 3 trial showed longer median PFS with IO102–IO103 plus pembrolizumab versus pembrolizumab alone, narrowly missing statistical significance.
Context: Median follow-up of 23 months; favorable trends across subgroups; mild injection-site reactions.
Implication: May influence prescriber choice and payer reviews pending full data.
Aptar nasal delivery used in CastleVax Phase II COVID-19 trial [5] [US • 13 Jan 2026]
Key point: Aptar’s nasal delivery systems are used in Phase II testing of the CVAX-01 intranasal COVID-19 vaccine.
Context: Approximately 200 adults; six-month follow-up; comparison of safety and mucosal immunity versus injectable mRNA vaccine.
Implication: Could streamline initiation and adherence via needle-free vaccination.
AIM completes Phase III for diploid rabies vaccine [6] [China • 15 Jan 2026]
Key point: AIM reports Phase III completion for a diploid rabies vaccine with higher efficacy than existing products.
Context: Human diploid cell platform; flexible four-dose or five-dose regimens; commercial-scale facility established.
Implication: Introduces competition that may affect pricing and formulary access.
Moderna outlines seasonal respiratory vaccine strategy [7] [US • 13 Jan 2026]
Key point: Moderna plans a seasonal respiratory vaccine franchise anchored by COVID-19, RSV, and influenza products.
Context: JPM Healthcare Conference; three approved products with additional flu and combination vaccines in development.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Live-attenuated and mucosal vaccines could improve durability and coverage in outbreak-prone regions.
- Multivalent respiratory vaccines aim to simplify prevention strategies in older adults.
- Personalized cancer vaccines show early signals of durable immune control.
- Combination immunotherapy approaches continue to evolve beyond checkpoint inhibitors alone.
- Manufacturing and delivery innovations remain central to vaccine differentiation.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Vaccines archive on our research hub page.
FAQ
What is PanChol and how does it differ from existing cholera vaccines?
PanChol is a live-attenuated oral vaccine designed to mimic natural infection, potentially offering stronger immunity in a single dose compared with killed whole-cell vaccines [1].
Which pathogens do Clover’s Phase 2 vaccines target?
Clover’s candidates target RSV and hMPV, with one formulation also including PIV3, aimed at older adults [2].
What makes TG4050 unique among cancer vaccines?
TG4050 is individualized, encoding patient-specific neoantigens in an MVA vector to drive targeted T-cell responses [3].
Did the IO102–IO103 melanoma trial meet its primary endpoint?
The trial narrowly missed statistical significance for PFS but showed consistent clinical benefit trends and acceptable safety [4].
Why is intranasal delivery important for CVAX-01?
Intranasal delivery may induce mucosal immunity at the site of viral entry, complementing systemic immune responses [5].
How does Moderna plan to fund its long-term pipeline?
Moderna aims to generate durable cash flow from seasonal respiratory vaccines to support oncology and rare disease programs [7].
Entities / Keywords
PanChol; Vibrio cholerae O1; Mass General Brigham; Clover Biopharmaceuticals; SCB-1022; SCB-1033; RSV; hMPV; PIV3; TG4050; Transgene; HNSCC; IO102–IO103; pembrolizumab; AptarGroup; CastleVax; CVAX-01; AIM Vaccine; diploid rabies vaccine; Moderna; Spikevax; mResvia.
References
- https://www.cidrap.umn.edu/cholera/novel-cholera-vaccine-shows-promise-phase-1-trial
- https://www.cloverbiopharma.com/media/189.html
- https://www.targetedonc.com/view/phase-i-trial-of-neoantigen-vaccine-shows-100-dfs-rate-in-hnscc
- https://www.onclive.com/view/pd-l1-ido1-targeted-vaccine-therapy-is-safe-and-effective-in-advanced-melanoma
- https://www.businesswire.com/news/home/20260113832919/en/Aptars-Nasal-Vaccine-Delivery-Solutions-Featured-in-CastleVax-Phase-II-Clinical-Trial-of-an-Intranasal-COVID-19-Vaccine-Candidate
- https://www.prnewswire.com/apac/news-releases/aims-iterative-process-high-efficiency-diploid-rabies-vaccine-completes-phase-iii-clinical-trials-efficacy-significantly-higher-than-existing-market-products-302661364.html
- https://www.pharmexec.com/view/jp-morgan-2026-moderna-planning-seasonal-respiratory-vaccine-franchise